UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pembrolizumab for Early Triple-Negative Breast Cancer

The New England journal of medicine, 2020-02, Vol.382 (9), p.810-821

2020

Volltextzugriff (PDF)

Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer

The New England journal of medicine, 2022-07, Vol.387 (3), p.217-226

2022

Volltextzugriff (PDF)

Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review

Breast cancer research : BCR, 2019-12, Vol.21 (1), p.143-143, Article 143

2019

Volltextzugriff (PDF)

Molecular pathways: autophagy in cancer--a matter of timing and context

Clinical cancer research, 2015-02, Vol.21 (3), p.498-504

2015

Volltextzugriff (PDF)

Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer

Clinical cancer research, 2018-06, Vol.24 (12), p.2804-2811

2018

Volltextzugriff (PDF)

Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis

Genes & development, 2011-03, Vol.25 (5), p.460-470

2011

Volltextzugriff (PDF)

Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesis

Genes & development, 2007-07, Vol.21 (13), p.1621-1635

2007

Volltextzugriff (PDF)

Pembrolizumab for Early Triple-Negative Breast Cancer

The New England journal of medicine, 2020-02, Vol.382 (9), p.810-821

2020

Volltextzugriff (PDF)

Abstract PD5-03: Relationship between tumor-infiltrating lymphocytes (TILs) and outcomes in the KEYNOTE-119 study of pembrolizumab vs chemotherapy for previously treated metastatic triple-negative breast cancer (mTNBC)

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.PD5-03-PD5-03

2020

Volltextzugriff (PDF)

Autophagy inhibition by chloroquine sensitizes HT-29 colorectal cancer cells to concurrent chemoradiation

World journal of gastrointestinal oncology, 2014-03, Vol.6 (3), p.74-82

2014

Volltextzugriff (PDF)

Results from the randomized KEYNOTE-355 study of pembrolizumab plus chemotherapy for Asian patients with advanced TNBC

NPJ breast cancer, 2024-09, Vol.10 (1), p.79-9, Article 79

2024

Volltextzugriff (PDF)

Contribution of tumour and immune cells to PD‐L1 expression as a predictive biomarker in metastatic triple‐negative breast cancer: exploratory analysis from KEYNOTE‐119

The journal of pathology. Clinical research, 2024-05, Vol.10 (3), p.e12371-n/a

2024

Volltextzugriff (PDF)

p62: a hub of multiple signaling pathways in HER2-induced mammary tumorigenesis

Molecular & cellular oncology, 2015-07, Vol.2 (3), p.e975035-e975035

2015

Volltextzugriff (PDF)

338 Effects of pembrolizumab on the tumor microenvironment (TME) after one presurgery treatment cycle in patients with triple-negative breast cancer (TNBC): phase 1b KEYNOTE-173 study

Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A364-A364

2021

Volltextzugriff (PDF)

Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer

The New England journal of medicine, 2022-02, Vol.386 (6), p.556-567

2022

Volltextzugriff (PDF)

Role of the polarity determinant crumbs in suppressing mammalian epithelial tumor progression

Cancer research (Chicago, Ill.), 2008-06, Vol.68 (11), p.4105-4115

2008

Volltextzugriff (PDF)

Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis

Cancer research (Chicago, Ill.), 2020-12, Vol.80 (24), p.5427-5434

2020

Volltextzugriff (PDF)

Bcl-2 Modulation to Activate Apoptosis in Prostate Cancer

Molecular cancer research, 2009-09, Vol.7 (9), p.1487-1496

2009

Volltextzugriff (PDF)

Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study

Clinical cancer research, 2021-06, Vol.27 (11), p.3061-3068

2021

Volltextzugriff (PDF)

Abstract CT069: KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC)

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.CT069-CT069

2017

Volltextzugriff (PDF)

Autophagy opposes p53-mediated tumor barrier to facilitate tumorigenesis in a model of PALB2-associated hereditary breast cancer

Cancer discovery, 2013-08, Vol.3 (8), p.894-907

2013

Volltextzugriff (PDF)

Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer

The New England journal of medicine, 2024-09

2024

Volltextzugriff (PDF)

Association between event-free survival and overall survival in early-stage triple-negative breast cancer

Future oncology (London, England), 2024-02, Vol.20 (6), p.335-348

2024

Volltextzugriff (PDF)

Evaluation of Pathologic Complete Response as a Surrogate for Long-Term Survival Outcomes in Triple-Negative Breast Cancer

Journal of the National Comprehensive Cancer Network, 2020-08, Vol.18 (8), p.1096-1104

2020

Volltextzugriff (PDF)

Abstract OT-30-01: KEYLYNK-009: A phase 2/3, open-label, randomized study of pembrolizumab plus olaparib vs pembrolizumab plus chemotherapy after induction with first-line pembrolizumab plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.OT-30-01-OT-30-01

2021

Volltextzugriff (PDF)

1 – 25 von 66

Suche als RSS-Feed

Aktive Filter

KollektionIngentaConnect

KollektionSpringerLINK Contemporary (Konsortium Baden-Württemberg)

Zeitschrift / SerieJournal Of Clinical Oncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(60)
Mit Volltextzugriff
(53)

Publikationsform

Sprache

Englisch
(66)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(28)
Science & Technology
(28)
Oncology
(18)
Humans
(15)
Animals
(14)
Female
(11)
Mice
(10)
Breast Cancer
(9)
Chemotherapy
(7)
Autophagy
(6)
Monoclonal Antibodies
(6)
Targeted Cancer Therapy
(6)
Triple Negative Breast Neoplasms - Drug Therapy
(6)
Tumors
(6)
Apoptosis
(5)
Cancer Therapies
(5)
Immunotherapy
(5)
Middle Aged
(5)
Patients
(5)
Pembrolizumab
(5)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Pembrolizumab for Early Triple-Negative Breast Cancer

Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer

Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review

Molecular pathways: autophagy in cancer--a matter of timing and context

Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer

Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis

Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesis

Pembrolizumab for Early Triple-Negative Breast Cancer

Abstract PD5-03: Relationship between tumor-infiltrating lymphocytes (TILs) and outcomes in the KEYNOTE-119 study of pembrolizumab vs chemotherapy for previously treated metastatic triple-negative breast cancer (mTNBC)

Autophagy inhibition by chloroquine sensitizes HT-29 colorectal cancer cells to concurrent chemoradiation

Results from the randomized KEYNOTE-355 study of pembrolizumab plus chemotherapy for Asian patients with advanced TNBC

Contribution of tumour and immune cells to PD‐L1 expression as a predictive biomarker in metastatic triple‐negative breast cancer: exploratory analysis from KEYNOTE‐119

p62: a hub of multiple signaling pathways in HER2-induced mammary tumorigenesis

338 Effects of pembrolizumab on the tumor microenvironment (TME) after one presurgery treatment cycle in patients with triple-negative breast cancer (TNBC): phase 1b KEYNOTE-173 study

Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer

Role of the polarity determinant crumbs in suppressing mammalian epithelial tumor progression

Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis

Bcl-2 Modulation to Activate Apoptosis in Prostate Cancer

Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study

Abstract CT069: KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC)

Autophagy opposes p53-mediated tumor barrier to facilitate tumorigenesis in a model of PALB2-associated hereditary breast cancer

Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer

Association between event-free survival and overall survival in early-stage triple-negative breast cancer

Evaluation of Pathologic Complete Response as a Surrogate for Long-Term Survival Outcomes in Triple-Negative Breast Cancer

Abstract OT-30-01: KEYLYNK-009: A phase 2/3, open-label, randomized study of pembrolizumab plus olaparib vs pembrolizumab plus chemotherapy after induction with first-line pembrolizumab plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)

Aktive Filter

Suchergebnisse filtern